Skip to main content
Top
Published in: BMC Nephrology 1/2003

Open Access 01-12-2003 | Research article

Medication-related problem type and appearance rate in ambulatory hemodialysis patients

Authors: Harold J Manley, Debra K Drayer, Richard S Muther

Published in: BMC Nephrology | Issue 1/2003

Login to get access

Abstract

Background

Hemodialysis (HD) patients are at risk for medication-related problems (MRP). The MRP number, type, and appearance rate over time in ambulatory HD patients has not been investigated.

Methods

Randomly selected HD patients were enrolled to receive monthly pharmaceutical care visits. At each visit, MRP were identified through review of the patient chart, electronic medical record, patient interview, and communications with other healthcare disciplines. All MRP were categorized by type and medication class. MRP appearance rate was determined as the number of MRP identified per month/number of months in study. The number of MRP per patient-drug exposures were determined using: {[(number of patients) × (mean number of medications)]/(number of months of study)} /number of MRP identified. Results were expressed as mean ± standard deviation or percentages.

Results

Patients were 62.6 ± 15.9 years old, had 6.4 ± 2.0 comorbid conditions, were taking 12.5 ± 4.2 medications, and 15.7 ± 7.2 doses per day at baseline. Medication-dosing problems (33.5%), adverse drug reactions (20.7%), and an indication that was not currently being treated (13.5%) were the most common MRP. 5,373 medication orders were reviewed and a MRP was identified every 15.2 medication exposures. Overall MRP appearance rate was 0.68 ± 0.46 per patient per month.

Conclusion

MRP continue to occur at a high rate in ambulatory HD patients. Healthcare providers taking care of HD patients should be aware of this problem and efforts to avoid or resolve MRP should be undertaken at all HD clinics.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kohn LT, Corrigan JM, Donaldson MS, eds: To err is human: building a safer health system. 1999, Washington, D.C.: National Academy Press Kohn LT, Corrigan JM, Donaldson MS, eds: To err is human: building a safer health system. 1999, Washington, D.C.: National Academy Press
2.
go back to reference Ernst FR, Grizzle AJ: Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc(wash). 2001, 41 (2): 192-9.CrossRef Ernst FR, Grizzle AJ: Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc(wash). 2001, 41 (2): 192-9.CrossRef
3.
go back to reference Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998, 279: 1200-1205. 10.1001/jama.279.15.1200.CrossRefPubMed Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998, 279: 1200-1205. 10.1001/jama.279.15.1200.CrossRefPubMed
4.
go back to reference Nelson KM, Talbert RL: Drug-related hospital admissions. Pharmacotherapy. 1996, 16 (4): 701-707.PubMed Nelson KM, Talbert RL: Drug-related hospital admissions. Pharmacotherapy. 1996, 16 (4): 701-707.PubMed
5.
go back to reference Ebbesen J, Buajordet I, Erikssen J, Brors O, Hilberg J, Svaar H, Sandvik L: Drug-related deaths in a department of internal medicine. Arch Intern Med. 2001, 161: 2317-2323. 10.1001/archinte.161.19.2317.CrossRefPubMed Ebbesen J, Buajordet I, Erikssen J, Brors O, Hilberg J, Svaar H, Sandvik L: Drug-related deaths in a department of internal medicine. Arch Intern Med. 2001, 161: 2317-2323. 10.1001/archinte.161.19.2317.CrossRefPubMed
6.
go back to reference Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, Segen DL, Shu K, Federico F, Leape LL, Bates DW: Adverse drug events in ambulatory care. N Engl J Med. 2003, 348 (16): 1556-1564. 10.1056/NEJMsa020703.CrossRefPubMed Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, Segen DL, Shu K, Federico F, Leape LL, Bates DW: Adverse drug events in ambulatory care. N Engl J Med. 2003, 348 (16): 1556-1564. 10.1056/NEJMsa020703.CrossRefPubMed
7.
go back to reference U.S. Renal Data System: USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. 2002, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD U.S. Renal Data System: USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. 2002, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
8.
go back to reference Hepler CD, Strand LM: Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990, 47: 533-543.PubMed Hepler CD, Strand LM: Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990, 47: 533-543.PubMed
9.
go back to reference Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI, Bates DW: Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999, 282: 267-270. 10.1001/jama.282.3.267.CrossRefPubMed Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI, Bates DW: Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999, 282: 267-270. 10.1001/jama.282.3.267.CrossRefPubMed
10.
go back to reference Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM: Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med. 1999, 159: 1939-45. 10.1001/archinte.159.16.1939.CrossRefPubMed Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM: Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med. 1999, 159: 1939-45. 10.1001/archinte.159.16.1939.CrossRefPubMed
11.
go back to reference United States Renal Data Systems (USRDS) 1998 Annual Data Report, National Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases, Bethesda, MD. 1998 United States Renal Data Systems (USRDS) 1998 Annual Data Report, National Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases, Bethesda, MD. 1998
12.
go back to reference Grabe DW, Low CL, Bailie GR, Eisele G: Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol. 1997, 47: 117-121.PubMed Grabe DW, Low CL, Bailie GR, Eisele G: Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol. 1997, 47: 117-121.PubMed
13.
go back to reference Kaplan B, Mason NA, Shimp LA, Ascione FJ: Chronic hemodialysis patients. Part I: Characterization and drug-related problems. Ann Pharmacother. 1994, 28: 316-319.PubMed Kaplan B, Mason NA, Shimp LA, Ascione FJ: Chronic hemodialysis patients. Part I: Characterization and drug-related problems. Ann Pharmacother. 1994, 28: 316-319.PubMed
14.
go back to reference Kaplan B, Shimp LA, Mason NA, Ascione FJ: Chronic hemodialysis patients. Part II: reducing drug-related problems through application of the focused drug therapy review program. Ann Pharmacother. 1994, 28: 320-4.PubMed Kaplan B, Shimp LA, Mason NA, Ascione FJ: Chronic hemodialysis patients. Part II: reducing drug-related problems through application of the focused drug therapy review program. Ann Pharmacother. 1994, 28: 320-4.PubMed
15.
go back to reference Stoutakis VA, Acchiardo SR, Martinez DR, Lorisch D, Wood GC: Role-effectiveness of the pharmacist in the treatment of hemodialysis patients. Am J Hosp Pharm. 1978, 35: 62-65. Stoutakis VA, Acchiardo SR, Martinez DR, Lorisch D, Wood GC: Role-effectiveness of the pharmacist in the treatment of hemodialysis patients. Am J Hosp Pharm. 1978, 35: 62-65.
16.
go back to reference Tang I, Vrahnos D, Hatoum H, Lau A: Effectiveness of clinical pharmacist interventions in a hemodialysis unit. Clin Ther. 1993, 15: 459-464.PubMed Tang I, Vrahnos D, Hatoum H, Lau A: Effectiveness of clinical pharmacist interventions in a hemodialysis unit. Clin Ther. 1993, 15: 459-464.PubMed
17.
go back to reference Manley HJ, McClaran ML, Overbay DK, Wright MA, Reid GM, Bender WL, Neufeld TK, Hebbar S, Muther RS: Factors Associated with Medication-Related Problems in Ambulatory Hemodialysis Patients. Am J Kidney Dis. 2003, 41: 386-393. 10.1053/ajkd.2003.50048.CrossRefPubMed Manley HJ, McClaran ML, Overbay DK, Wright MA, Reid GM, Bender WL, Neufeld TK, Hebbar S, Muther RS: Factors Associated with Medication-Related Problems in Ambulatory Hemodialysis Patients. Am J Kidney Dis. 2003, 41: 386-393. 10.1053/ajkd.2003.50048.CrossRefPubMed
18.
go back to reference Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD: Drug-related problems: their structure and function. DICP. 1990, 24 (11): 1093-1097.PubMed Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD: Drug-related problems: their structure and function. DICP. 1990, 24 (11): 1093-1097.PubMed
19.
go back to reference Manley HJ, Bailie GR, Grabe DW: National database information: utility for an individual hemodialysis center. Am J Health-Syst Pharm. 2000, 57: 902-906.PubMed Manley HJ, Bailie GR, Grabe DW: National database information: utility for an individual hemodialysis center. Am J Health-Syst Pharm. 2000, 57: 902-906.PubMed
20.
go back to reference McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ: Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic renal disease. Am Heart J. 2002, 144: 226-232. 10.1067/mhj.2002.125513.CrossRefPubMed McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ: Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic renal disease. Am Heart J. 2002, 144: 226-232. 10.1067/mhj.2002.125513.CrossRefPubMed
21.
go back to reference Dhingra RK, Stack AG, Wolfe RA, Yevzlin A, Port FK: Low utilization of cardiovascular drugs among incident dialysis patients with cardiac disease: A national study. J Am Soc Nephrol. 2001, 12: A1035- Dhingra RK, Stack AG, Wolfe RA, Yevzlin A, Port FK: Low utilization of cardiovascular drugs among incident dialysis patients with cardiac disease: A national study. J Am Soc Nephrol. 2001, 12: A1035-
22.
go back to reference Bragg JL, Mason NA, Maroni BJ, Held PJ, Young EW: Beta-adrenergic antagonist utilization among hemodialysis (HD) patients. J Am Soc Nephrol. 2001, 12: A1652- Bragg JL, Mason NA, Maroni BJ, Held PJ, Young EW: Beta-adrenergic antagonist utilization among hemodialysis (HD) patients. J Am Soc Nephrol. 2001, 12: A1652-
23.
go back to reference Manley HJ, Overbay DO, Reid G, Bender W, Neufeld T, Hebbar S, Muther RS: Medical treatment of hemodialysis (HD) patients' cardiovascular risk factors (CVRF): potential for drug-related problems. J Am Soc Nephrol. 2002, 13: 703A-(PUB158) Manley HJ, Overbay DO, Reid G, Bender W, Neufeld T, Hebbar S, Muther RS: Medical treatment of hemodialysis (HD) patients' cardiovascular risk factors (CVRF): potential for drug-related problems. J Am Soc Nephrol. 2002, 13: 703A-(PUB158)
24.
go back to reference Mason NA, Bailie GR, Johnson CA, St Peter WL, Bragg JL, Young EW: Underutilization of HMG-CoA reductase inhibitors (HMGCoAIs) among hemodialysis (HD) patients: a potential drug-related problem. J Am Soc Nephrol. 2001, 12: A1739- Mason NA, Bailie GR, Johnson CA, St Peter WL, Bragg JL, Young EW: Underutilization of HMG-CoA reductase inhibitors (HMGCoAIs) among hemodialysis (HD) patients: a potential drug-related problem. J Am Soc Nephrol. 2001, 12: A1739-
25.
go back to reference Manley HJ, Carroll C: The clinical and economic impact of pharmaceutical care in end-stage renal disease patients. Seminar Dial. 2002, 15 (1): 45-9. 10.1046/j.1525-139x.2002.00014.x.CrossRef Manley HJ, Carroll C: The clinical and economic impact of pharmaceutical care in end-stage renal disease patients. Seminar Dial. 2002, 15 (1): 45-9. 10.1046/j.1525-139x.2002.00014.x.CrossRef
Metadata
Title
Medication-related problem type and appearance rate in ambulatory hemodialysis patients
Authors
Harold J Manley
Debra K Drayer
Richard S Muther
Publication date
01-12-2003
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2003
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-4-10

Other articles of this Issue 1/2003

BMC Nephrology 1/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.